Smith C R, Jaramillo A, Liu W, Tu Y, Kaleem Z, Swanson C J, Mohanakumar T
Transplantation Section, Department of Surgery, Washington University School of Medicine, Box 8109-3328.CSRB, 660 South Euclid Avenue, St. Louis, MO 63110-1093, USA.
Transplantation. 2001 Jun 15;71(11):1640-8. doi: 10.1097/00007890-200106150-00025.
To further define the role of indirect allorecognition, cardiac allografts from HLA-A2-transgenic (HLA-A2+) C57BL/6 mice were heterotopically transplanted into normal C57BL/6, CD4 T cell-knockout (KO) C57BL/6 mice, CD8 T cell-KO C57BL/6 mice, fully MHC-discordant BALB/c mice (allogeneic control), and HLA-A2+ C57BL/6 mice (syngeneic control). HLA-A2+ grafts were acutely rejected when transplanted into BALB/c mice (mean survival time: 10+/-0.8 days), normal C57BL/6 mice (mean survival time: 16.5+/-2.1 days) as well as CD8-KO mice (mean survival time: 12.8+/-1.3 days). Histopathological analysis revealed classical acute cellular rejection with moderate to severe diffuse interstitial CD4+ and CD8+ cellular infiltrates and significant intra-graft deposition of IgG and complement. In contrast, HLA-A2+ grafts were not rejected when transplanted into CD4-KO mice or HLA-A2+ mice. CD8-KO recipients treated with an anti-CD4 monoclonal antibody, but not with an anti-NK monoclonal antibody, failed to reject their allografts with prolonged administration of antibody (30 days). Spleen cells from mice rejecting HLA-A2+ allografts failed to lyse HLA-A2+ target cells indicating a lack of involvement of CD8+ T cells in the rejection process. In contrast, spleen cells from rejecting animals proliferated significantly to both HLA-A2+ cells and to a peptide derived from the HLA-A2 molecule. Development of anti-HLA-A2 antibodies was observed in all animals rejecting HLA-A2+ allografts. These results suggest that indirect allorecognition of donor MHC class I molecules leads to rejection of cardiac allografts and development of alloantibodies in this unique transplant model in which there is a single MHC discordance between donor and recipient.
为了进一步明确间接同种异体识别的作用,将来自HLA - A2转基因(HLA - A2 +)C57BL / 6小鼠的心脏同种异体移植物异位移植到正常C57BL / 6、CD4 T细胞敲除(KO)的C57BL / 6小鼠、CD8 T细胞敲除的C57BL / 6小鼠、完全MHC不匹配的BALB / c小鼠(同种异体对照)和HLA - A2 + C57BL / 6小鼠(同基因对照)体内。当HLA - A2 +移植物移植到BALB / c小鼠(平均存活时间:10±0.8天)、正常C57BL / 6小鼠(平均存活时间:16.5±2.1天)以及CD8敲除小鼠(平均存活时间:12.8±1.3天)体内时,会发生急性排斥反应。组织病理学分析显示典型的急性细胞排斥反应,伴有中度至重度弥漫性间质CD4 +和CD8 +细胞浸润以及移植物内显著的IgG和补体沉积。相比之下,当HLA - A2 +移植物移植到CD4敲除小鼠或HLA - A2 +小鼠体内时,未发生排斥反应。用抗CD4单克隆抗体而非抗NK单克隆抗体处理的CD8敲除受体,在长时间给予抗体(30天)后未能排斥其同种异体移植物。排斥HLA - A2 +同种异体移植物的小鼠的脾细胞未能裂解HLA - A2 +靶细胞,表明CD8 + T细胞未参与排斥过程。相反,来自排斥动物的脾细胞对HLA - A2 +细胞和源自HLA - A2分子的肽均有显著增殖。在所有排斥HLA - A2 +同种异体移植物的动物中均观察到抗HLA - A2抗体的产生。这些结果表明,在供体和受体之间仅存在单一MHC不匹配的这种独特移植模型中,对供体MHC I类分子的间接同种异体识别导致心脏同种异体移植物的排斥和同种异体抗体的产生。